All In Biotech

BLA 761123 · Astrazeneca Ab

Saphnelo

Anifrolumab-Fnia · Injection · Type I Interferon Receptor Antagonist

Novel

CDER novel approval, Jul 30, 2021: To treat moderate-to severe systemic lupus erythematousus along with standard therapy

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 30, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

32

11 Phase 3, 14 recruiting

FAERS reports

1,921

1,057 serious, 81 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 25, 2026.

SAPHNELO is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. SAPHNELO is a type I interferon (IFN) receptor antagonist indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. ( 1 )

Mechanism: Anifrolumab-fnia is a human IgG1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR) with high specificity and affinity. This binding inhibits type I IFN signaling, thereby blocking the biologic activity of type I IFNs. Anifrolumab-fnia also induces the internalization of IFNAR1, thereby reducing the levels of cell surface IFNAR1 available for receptor assembly. Blockade of receptor mediated type I IFN signaling inhibits IFN responsive gene expression as well as downstream inflammatory and immunological processes. Inhibition of type I IFN blocks plasma cell...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SAPHNELO · ANIFROLUMAB-FNIA 300MG/2ML(150MG/ML) · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Anifrolumab" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • systemic lupus erythematosus168
  • fatigue147
  • arthralgia109
  • headache98
  • nausea88
  • pain79
  • rash78
  • herpes zoster69
  • drug ineffective67
  • product dose omission issue62
  • condition aggravated59
  • dyspnoea55

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
202123
2022191
2023383
2024478
2025465
2026381

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Saphnelo (Anifrolumab-Fnia)

2024 spending

$13.5M

Beneficiaries

417

2,642 claims

Per beneficiary

$32,279

$2,530.92 per unit

View as table
YearSpending
2020$0
2021$390,473
2022$4,315,125
2023$8,818,021
2024$13,460,205

Part B: Saphnelo (Anifrolumab-Fnia) · HCPCS J0491

2024 spending

$64.6M

Beneficiaries

1,877

12,979 claims

Per beneficiary

$34,410

2024 ASP limit $17.23 per unit

View as table
YearSpending
2020$0
2021$0
2022$15,474,476
2023$39,863,663
2024$64,586,680

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 62 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.